News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Total investment incurred for setting up the new R&D Rs 250 crore
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The acquisition is based on an enterprise value of Rs. 1,660 crore
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Subscribe To Our Newsletter & Stay Updated
